INVESTOR RELATIONS
(TSXV:VPT, OTC:VPTDF)
Ventripoint Diagnostics Ltd is a medical device company that is primarily engaged in the development and commercialization of cardiac diagnostic tools. It sells its products worldwide.
CAPITAL STRUCTURE
Symbol: TSX-V: VPT & OTC: VPTDF
Shares Outstanding 127M
Shares Fully Diluted 148M
Recent Share Price CDN$.32
52-Week Range CDN$.07-.325
Market Cap ca. CDN$40M
Insider Ownership (FD) 6%
Public Float Ownership 94%
Debt None
Cash 2 years
Liquidity CDN$600,000/day
Read full report
KEY AND STRAGETIC GOALS
2020
Read More
Ventripoint has entered into a collaboration with the Veterinary Hospital at the North Carolina State University (NCSU) to test and evaluate the use of the VMS+ in echocardiography of canines with the goal of expanding this technology to all animals.
VMS+ could eventually help treat our most loyal best friend.
EXPLORING NEW FRONTIERS FOR VMS+
LATEST FINANCIAL DATA
Quarterly Reports
Annual Reports
LATEST PRESS RELEASES
LATEST EVENTS
FEB
11
​
Ventripoint CEO interviewed on TraderTV Live
FEB
04
​
Ventripoint CEO interviewed by Torrey Hills Capital
INVESTOR RELATIONS TEAM
Clay Chase
Torrey Hills Investor Relations
(858) 456-7300
Jonathan Robinson
Oak Hill Financial
(416) 669-1001
Adrian Sydenham
MarketSmart Communications Inc.
(877) 261-4466